South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-12-17
DOI
10.3389/fphar.2018.01480
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Efficacy and Safety of Long-term Pirfenidone Therapy in Patients with Idiopathic Pulmonary Fibrosis
- (2018) Kazumasa Ogawa et al. INTERNAL MEDICINE
- Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece
- (2018) Argyrios Tzouvelekis et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
- (2018) Eva Brunnemer et al. RESPIRATION
- A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis
- (2018) Sergio Harari et al. RESPIRATION
- Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
- (2018) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study
- (2017) Argyrios Tzouvelekis et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)
- (2017) Ulrich Costabel et al. RESPIRATION
- Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions
- (2017) Jonathan A. Galli et al. RESPIROLOGY
- Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
- (2016) Francesco Bonella et al. RESPIRATION
- Nintedanib and Pirfenidone. New Antifibrotic Treatments Indicated for Idiopathic Pulmonary Fibrosis Offer Hopes and Raises Questions
- (2015) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
- (2015) Paul W. Noble et al. EUROPEAN RESPIRATORY JOURNAL
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
- (2014) Talmadge E. King et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-Life Experience from a German Tertiary Referral Center for Interstitial Lung Diseases
- (2014) Ute Oltmanns et al. RESPIRATION
- Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
- (2014) Dominique Valeyre et al. RESPIROLOGY
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
- (2011) Paul W Noble et al. LANCET
- Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
- (2011) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The rising incidence of idiopathic pulmonary fibrosis in the UK
- (2011) V. Navaratnam et al. THORAX
- Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis
- (2008) Hisashi Oku et al. EUROPEAN JOURNAL OF PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search